Company: BIAF
Filing Date: 2025-04-15
Form Type: PRE 14A
Source: 0001641172-25-004857
Chunk: 18

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-04-15
Form: PRE 14A
Chunk 18
---
 certain risks and overseeing the management of such risks, the full Board is regularly informed of such
risks through committee reports and otherwise. While the Board oversees the Company’s overall risk management, the day-to-day management
processes are executed by the Company’s management team. The Company believes that division of responsibilities enables the Company
to address risks most effectively.

Role of the Board in Human Capital Oversight

The Company places significant emphasis on the recruitment,
development, and retention of its employees who include award-winning scientists dedicated to advancing scientific discovery from bench
to bedside. We employ 57 employees at the time of this filing, 21 employed by bioAffinity Technologies and 36 employed by PPLS. We place
significant emphasis on the recruitment, development, and retention of our employees who include award-winning scientists dedicated to
advancing scientific discovery from bench to bedside. Of our seven employees engaged in research and development, all of whom are employed
full-time, three hold Ph.Ds in biology or medicinal chemistry. Of the 36 employees at PPLS, nearly 40% have worked at our clinical laboratory
for more than five years.

Our Chief Science Officer, William Bauta, Ph.D., was
the Associate Director of Science at Genzyme Corporation and held a similar position at Ilex Products, Inc., where he was responsible
for the discovery, development and FDA approval of therapeutics in the companies’ pipelines, and Manager of Medicinal and Process
Chemistry at Southwest Research Institute. Business development is led by our Chief Operating Officer, Xavier Reveles, who has 25 years
of experience as a clinical geneticist skilled in the creation and management of CLIA clinical laboratories, coding, and CPT reimbursement
valuations. Mr. Reveles is board certified by the American Society of Clinical Pathology as a clinical specialist in cytogenetics who
has successfully launched multiple diagnostics and commercial laboratories. We have attracted experienced salespeople with a proven record
in the pulmonary field. In November 2023, we hired a National Sales Director who has more than 15 years of experience in medical sales
and marketing, most recently as Executive Account Manager for the respiratory portfolio of Olympus America’s therapeutic solutions
division. Our innovative and collaborative culture is in part responsible for our ability to attract and retain highly skilled professionals
seeking professional advancement. Outside partnerships and collaborations that advance business and scientific research are encouraged,
allowing us to multiply workforce efforts without expending significant capital.

The Board, led by the Compensation Committee,